Skip to content
Screener

Net Income at other companies

Pfizer logo
PfizerPFE
-$248M-109%
Amgen logo
AmgenAMGN
$2.38B+65.9%
Incyte logo
IncyteINCY
$585.61M+44.6%
PVL
Palvella TherapeuticsPVLA
-$15.77M-92.6%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
-$73.5M-29.9%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-$61.21M+20.1%

Segments

By segment

See full
Reportable Segment$15.01M+194%

Other financials

Income statement

See full
Revenue$129.9M+59.3%
Gross profit$118.9M+60.7%
Operating income$16.4M+212%
EPS (diluted)$0.11+185%

Balance sheet

See full
Cash & equivalents$34.4M-52.9%
Total debt$114.1M+3.6%
Total equity$220.6M+58.7%
Total assets$488.5M+38.6%

Cash flow

See full
Operating cash flow$12.6M
CapEx$158.0K+103%
Free cash flow$12.5M

Valuation

See full
Market cap$3.32B+81.4%
Enterprise value$3.4B+82.1%
P/S7.2×+0.2×

Profitability

See full
Gross margin91.1%+2.0pp
Operating margin-12%-5.7pp
Net margin-13.9%-6.6pp
FCF margin-52.5%-21.9pp

Returns & leverage

See full
Return on equity-28.2%-13.0pp
Debt / equity0.5×-0.3×
Current ratio2.9×-0.3×

Where this comes from

Reported directly by Arcutis Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The source filing: Arcutis Biotherapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:21 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001787306-26-000051
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Total other income (expense)(1,284)(933)(3,397)(1,185)
Income (loss) before income taxes15,145(15,544)3,943(40,325)
Provision for income taxes136342229621
Net income (loss)$15,009$(15,886)$3,714$(40,946)
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities(96)(95)(447)(232)
Foreign currency translation adjustment(46)200(165)204
Total other comprehensive income (loss)(142)105(612)(28)

Item 1. Financial Statements (Unaudited)

FAQ

What is Arcutis Biotherapeutics, Inc.'s net income?
Arcutis Biotherapeutics, Inc. (ARQT) reported net income of $15.01M in Q2 2026.
How has Arcutis Biotherapeutics, Inc.'s net income changed year-over-year?
Arcutis Biotherapeutics, Inc.'s net income increased by 194.5% year-over-year, from -$15.89M to $15.01M.
What is the long-term trend for Arcutis Biotherapeutics, Inc.'s net income?
Over 3 years (2021 to 2024), Arcutis Biotherapeutics, Inc.'s net income has grown at a -12.1% compound annual growth rate (CAGR), from -$206.36M to -$140.04M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.

Ask your AI about Arcutis Biotherapeutics, Inc.'s net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude